Clearline Capital’s Immunogen Inc IMGN Stock Holding History

Clearline Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-703,855	Closed	-$1.53M	–	68
2019 Q2	$1.53M	Buy	+703,855	New	+$1.66M	0.75%	34

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clearline Capital's IMGN Position: Q3 2019 in Review

Clearline Capital sold out of Immunogen Inc (IMGN) in Q3 2019, closing a stake of 703,855 shares — an estimated $1.53M sold.

Clearline Capital first reported a position in IMGN in Q2 2019 and held it in 1 quarter. The position peaked at $1.53M in Q2 2019. 189 funds tracked by Wall St. Rank hold IMGN as of Q3 2019.

Clearline Capital reported no remaining Immunogen Inc position as of Q3 2019 after selling out during the quarter.
Clearline Capital sold 703,855 Immunogen Inc shares in Q3 2019, an estimated $1.53M.
Clearline Capital first reported a position in Immunogen Inc in Q2 2019 and held it in 1 quarter.
Clearline Capital's Immunogen Inc position peaked at $1.53M in Q2 2019.
189 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2019.

Based on Clearline Capital's 13F filing for Q3 2019, filed 14 Nov 2019.